Journal of the neurological sciences · 2020
Description of 3 patients with myasthenia gravis and COVID-19.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rein Netaniel, Haham Nitzan, Orenbuch-Harroch Efrat, Romain Marc, Argov Zohar, Vaknin-Dembinsky Adi, Gotkine Marc
Аннотация
BACKGROUND: The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation.
CASE DESCRIPTION: We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.
CONCLUSION: Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.
CASE DESCRIPTION: We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.
CONCLUSION: Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.
Предметные рубрики MeSH
AdultAgedAzithromycinBetacoronavirusCOVID-19Coronavirus InfectionsDiabetes Mellitus, Type 2FemaleHumansHydroxychloroquineHypertensionHypothyroidismImmunocompromised HostImmunoglobulins, IntravenousImmunosuppressive AgentsLopinavirMaleMyasthenia GravisPandemicsPlasmapheresisPneumonia, ViralRitonavirSARS-CoV-2Treatment OutcomeCOVID-19 Drug Treatment